Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Accounts Payables (2023 - 2025)

Historic Accounts Payables for Contineum Therapeutics (CTNM) over the last 3 years, with Q3 2025 value amounting to $786000.0.

  • Contineum Therapeutics' Accounts Payables fell 4373.66% to $786000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $786000.0, marking a year-over-year decrease of 4373.66%. This contributed to the annual value of $1.8 million for FY2024, which is 18519.69% up from last year.
  • Contineum Therapeutics' Accounts Payables amounted to $786000.0 in Q3 2025, which was down 4373.66% from $2.0 million recorded in Q2 2025.
  • In the past 5 years, Contineum Therapeutics' Accounts Payables registered a high of $3.6 million during Q1 2025, and its lowest value of $570000.0 during Q1 2024.
  • Over the past 3 years, Contineum Therapeutics' median Accounts Payables value was $1.1 million (recorded in 2024), while the average stood at $1.4 million.
  • Data for Contineum Therapeutics' Accounts Payables shows a peak YoY increase of 53947.37% (in 2025) and a maximum YoY decrease of 4373.66% (in 2025) over the last 5 years.
  • Quarter analysis of 3 years shows Contineum Therapeutics' Accounts Payables stood at $635000.0 in 2023, then skyrocketed by 185.2% to $1.8 million in 2024, then plummeted by 56.6% to $786000.0 in 2025.
  • Its last three reported values are $786000.0 in Q3 2025, $2.0 million for Q2 2025, and $3.6 million during Q1 2025.